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PHARMACY
Advancement in Pharmacotherapy
Zarish Fatima –Trainee Pharmacist
	 •	 Daclatasvir	with	Sofosbuvir	for	HCV
On July 24th, 2015, the U.S.Food and Drug Administration (FDA) approved daclatasvir 
(oral tablet) in combination with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 
infections. Daclatasvir is the first drug that has demonstrated safety and efficacy to treat 
genotype 3 HCV infections without the need for co-administration of interferon or ribavi-
rin and can be used in patients with or without cirrhosis, but sustained virologic response 
is generally lower in the presence of cirrhosis.
	 •	 World’s	First	Malaria	Vaccine	gets	a	nod	by	European	Agency
On July 24th, 2015, the European Medicines Agency’s Committee for Medicinal Prod-
ucts for Human Use (CHMP) has adopted a positive scientific opinion for *Mosquirix 
vaccine(also known as RTS,S/AS01). The vaccine is intended for use in areas where 
malaria is regularly found, for the active immunization of children aged 6 weeks to 17 
months against malaria caused by the Plasmodium falciparum parasite, and against hepa-
titis B. Currently, the vaccine requires four doses. The first three happen a month apart 
from each other, and the fourth happens about 18 months later. After decades of research 
into malaria vaccinations, Mosquirix is the first vaccine for the disease to be assessed by 
a regulatory agency. Following this decision, the World Health Organization (WHO) will 
now formulate a policy recommendation on use of the vaccine in national immunization 
programmes once approved by national regulatory authorities.
Auxiliary	Labels-	Increasing	Health	Literacy	
among Patients
Nida Najmi-Clinical Pharmacist
Poor health literacy is related to increased emergency room visits, poor medication 
adherence and lowered overall health outcomes. Sometimes it is necessary to provide 
supplementary information regarding proper and safe administration, use, storage, 
interactions, precautions and common side effects of the medicine in addition to the 
information provided on typed label. Auxiliary labels are placed on drug containers to 
provide additional instructions or reinforce directions given on the regular label. 
According to the Institute of Medicine report, “Preventing Medication Errors”, cited poor 
labeling as a central cause for medication errors in the USA. Auxiliary labels can prevent 
several types of medication errors including missed dose, wrong dosage forms, wrong 
time interval, wrong route, etc. and ultimately decrease morbidity and mortality and cost 
of the therapy. 
Ambulatory care pharmacist is responsible for providing patient counseling upon receipt 
of an outpatient prescription after a review of the patient’s record. Alternative forms of 
patient information are used to support patient counseling, such as written information, 
leaflets and auxiliary labels on the prescription drugs. In order to provide better 
understanding of medications, easy-to-understand prescription auxiliary labels were 
developed both in English and Urdu. These colorful auxiliary labels promote adherence 
to medications and avoid treatment failure, helps patients cope with their disease and any 
*Currently Mosquirix vaccine is not available in local market.
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ZA is a 58-year-old man with a medical history of elevated low-density lipoprotein levels and well-controlled chronic stable angina 
(experiencing <1 angina attack per month) secondary to coronary artery disease (CAD). He presents to his primary care physician 
for a follow-up appointment after his blood pressure (BP) was found to be 165/94 mm Hg at his annual physical exam. At today’s 
visit, ZA’s BP is found to be 166/93 mm Hg, resulting in a diagnosis of hypertension. ZA is currently on atorvastatin 40 mg daily 
and metoprolol tartrate 100 mg twice daily, and he reported no adverse effects from either medication. He has no other medical 
history of note, and his resting heart rate is 65 to 70 beats per minute. ZA’s physician would like to start him on a new medication to 
help control his BP and called the pharmacy for advice.
What	would	be	an	appropriate	BP	goal	for	ZA,	and	how	would	you	help	him	achieve	it?
Find answer in the newsletter
Case Study
 
All suppositories and enemas.
Antacids, Tetracycline, Quinolone.
Levodopa, Metronidazole, Nitrofurantoin, Rifampin, Daunorubicin, Doxorubicin.
Sulfamethazole/Trimethoprim, Bisphosphonates, Sulfasalazines.
Enteric coated formulations, any drug that end with XR, ER, LA, SR, CR, CRT, SA, TR, TD.
Simvastatin, Atorvastatin, Amiodarone, Buspiron, Carbamazepine, Cyclosporine, Tacrolimus, Diazepam, Verapamil, 
Nicardipine, Felodipine, Nifedipine, Voriconazole.
ACE Inhibitor, Angiotensin Receptor Blockers, Carbamazepine, Isotretinoin, Lithium, NSAIDs, Phenytoin, 
Phenobarbital, Topiramate, Valproic Acid, Ribavirin, Misoprostol, Methotrexate, Leflunomide, Statins, Dutasteride, 
Finasteride, Warfarin, Lenalidomide, Thalidomide, Paroxetine
Inhalers, Rotahalers.
Any medicine that needs to be refrigerated.
Refrigerate
Do Not Freeze
Auxiliary Labels Medicines
All suspensions, Inhalers, Viscous topical liquids, AKU compounded suspensions.
Topicals, for the eyes, for the ear, for the nose, for rectal use only, for vaginal use only, not to be taken by mouth.
Analgesics with CNS effects, Antipsychotics, Some antidepressants including Mirtazapine and Trazodone, Dopamine 
agonists, Antihistamines, Anti-nauseants, Anticonvulsants, Skeletal muscle relaxants, All antidepressants Or Narcotic 
drugs, including Hypnotics-Controlled and not controlled.
Sulfa antibiotics, Tetracycline, Topical retinoid, Isotretinoin (Oral), and few other HIV drugs, NSAIDs (Piroxicam), 
Diclofenac, Some risk with Ibuprofen and Naproxen, Metronidazole, Isoniazid, Diuretics.
Ampicillin, Bisphosphonates, Captopril, Proton Pump Inhibitors, Sildenafil, Levothyroxine, Mycophenolate, 
Tacrolimus, Sulphamethoxazole/ Trimethoprim, Voriconazole.Em
pt
y
Carvedilol, Itraconazole, metformin, phosphate binders, NSAIDs, Opioids, steroids.
medication side effects that might occur and important to avoid potential drug interactions with OTC and prescription medications. 
These auxiliary labels are specifically developed in order to increase health literacy among the patients who are on prolonged drug 
therapy.
Following is the list of medications requiring auxiliary label: 
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How	to	Take	Oral	Diabetic	Medications	with	Food,	Nutrient/Herb	
and	other	Medications?
Dr. Qurat-ul-ain Hafeez, Pharmacist
 
Avoid in Lactic acidosis: renal 
insufficiency (sr. creatinine 
≥1.5mg/dl in males or ≥1.4mg/
dl in females) or creatinine 
clearance rate <70-80 ml/min, & 
hypoxic states 
 
-Caution in renal and liver 
dysfunctioning 
-Hypoglycemia.
-Increased risk of 
Sulfonylurea-induced hemolytic 
anemia in G6PD deficiency.
Fluid retention.
-If ALT>2.5 times ULN, don’t 
start therapy; stop if ALT> 
3times ULN. 
-Avoid in Peripheral/pulmonary 
edema, heart failure. 
-Reduced bone density/osteo-
porosis.
-Avoid in overweight/obese 
patients.
-Avoid pioglitazone in patient 
has a history of bladder cancer.
-Not recommended in significant 
renal impairment 
-Not recommended in Crohn’s 
disease, ulcerative colitis  or 
short bowel syndrome 
-Caution in renal 
dysfunction & history of pan-
creatitis
Drug Recommendation Regarding	Food
Drug-Nutrients	/Herbs	
Interactions Drug-Disease InteractionsOther	Medication	Interactions
- Contrast   media (iodinated) may result 
acute renal failure or lactic acidosis. 
D/C metformin 48 hour before and after 
imaging. 
-Cimetidine may compete with metfor-
min for renal elimination.
- Antacid, PPI & H2 blockers increase 
its effect by increasing gastric  pH          
(enhance its absorption)
-NSAIDs & fibrates displace 
Sulfonylurea from protein 
binding sites and increase its effect.
-With inducers/inhibitors of CYP2C9
Co-administration of glyburide with 
bosentan increases the risk of liver 
enzymes elevation
-It increases effect of  valsartan
- Insulin may increase the  fluid retention 
a/s with TZ.
- With strong   inducer/ inhibitor of 
CYP2C8
-may decrease digoxin absorption. 
-may increase effect of warfarin. 
Action: space 
administration.
-Its effect enhance by  colestyramine.
-Increases plasma concentration of 
digoxin.
-Limit saxagliptin dose to 2.5mg/day 
when co-administered with strong 
CYP3A4 inhibitors & with CYP3A4 
inducers.
   ----
Vitamin B12 /folic acid 
depletion.
Caution with garlic, 
gymnema, chromium 
(may  cause hypoglycemia) 
Sulfonylureas
Caution with alfalfa, aloe, 
bitter melon, fenugreek, 
garlic, ginger, ginseng, 
gymnema, marsh mallow etc. 
Caution with garlic, 
gymnema, chromium (may 
cause hypoglycemia)
Caution  with alfalfa, aloe, 
bitter melon, fenugreek, 
garlic, ginger, ginseng, 
gymnema, marsh mallow 
etc. 
------
-Caution with alfalfa, aloe, 
bitter melon, fenugreek, 
garlic, ginger, ginseng, 
gymnema, marsh mallow, 
St John’s wort  etc.
-Avoid pomegranate juice 
as much as possible.
None
Avoid mangoes, oranges, 
dragon fruits, rambutans, 
passion fruits, pawpaws, 
wild grapes, pomegranates, 
wild mullberies, and kiwis.
None
None
Should be taken with food to 
limit GI side effects.
Taken 30 minutes before 
meals to avoid erratic 
absorption.
Administered with first main 
meal of the day.
Administered with first main 
meal of the day. 
Administered first main meal 
of the day.
Administered without regard 
to meals.
Administered with the first 
bite of each main meal.
Administered with or with-
out food.
Administered without regard 
to meals. 
-Administered 
with or without food.
Metformin
Glipizide
(Substrate of 
CYP2C9)
Glimepiride
(Substrate of 
CYP2C9)
Glibenclamide	/
Glyburide
(Substrate of 
CYP2C9)
Gliclazide
(Substrate of 
CYP2C9)
Pioglitazone
(Substrate of 
CYP2C8)
Rosiglitazone
(Substrate of 
CYP2C8)
Acarbose
Sitagliptin
Saxagliptin
(Substrate of 
CYP3A4)
Vildagliptin
Sulfonylureas
Thiazolidenedione
Biguanides
Alpha Glucosidase Inhibitors
DPP4 Inhibitors
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The Aga Khan University Hospital, Karachi
Newsletter	Feedback	
Please help us to improve our newsletter by filling the online feedback form through below link:
https://docs.google.com/forms/d/1ic4R7RJZcco6x8zHpFc6PZhM4HpjmDWUcVyRs1yVjzM/viewform?usp=send_form
Proud to Report
Annual Iftar party organized by Department of Pharmacy  Services on July 7th, 2015 at Tea-garden sports complex , (AKUH)
Various sessions conducted for the residents and nursing staff in AKUH auditorium for training of the “Heparin infusion protocol 
and guidelines” developed.
According to the recently released American Heart Association/ American Society of Cardiology/American Society of Hypertension 
guidelines, a patient with chronic stable angina and hypertension should have a BP goal of <140/90 mm Hg to prevent 
cardiovascular events. In addition to diet and lifestyle modifications, beta-blockers are the medication of choice to control the BP of 
a patient with chronic stable angina. If beta-blocker therapy is inadequate to concomitantly treat a patient’s CAD and hypertension 
or is poorly tolerated, the guidelines suggest adding an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor 
blocker to the patient’s medication regimen. This can be then be followed by a thiazide or thiazide-like diuretics, if necessary. ZA 
has tolerated beta-blocker therapy well, and his heart rate is well controlled at 65 to 70 beats per minute at his current (and maximal) 
dose of metoprolol. At this time, his physician could consider adding an ACE inhibitor, such as lisinopril 5 mg once daily, to his 
medication regimen.
Answer:	Case	Study
Pharmacy Department Iftar Party 2015
Training	Sessions	on	Heparin	Infusion	Protocols	by	Pharmacy
